Virion X provides pseudotyped virus panels and high-throughput screening assays to support epidemiology, vaccine development, and antiviral drug discovery. The company offers neutralisation assays, seroepidemiology, tropism studies, and bespoke virus development, with a focus on cost optimisation and rapid, reliable results. Their established virus panel and validated protocols help researchers accelerate milestones without troubleshooting assay development.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers developing vaccines and antiviral drugs need reliable, high-throughput screening tools to assess immune responses and drug efficacy, but building and validating viral assays in-house is time-consuming, costly, and technically demanding. This slows down research timelines and increases the risk of inconsistent or irreproducible data, particularly when working with high-consequence epidemic and pandemic viruses.
Solution
Virion X provides a comprehensive range of pseudotyped virus products and screening assay services that enable researchers to evaluate neutralising antibody responses, antiviral activity, and viral tropism without the need for in-house assay development. Their established panel of pseudotyped viruses covers a wide breadth of high-consequence pathogens, and their technology can be rapidly adapted to new virus targets. The company offers neutralisation assays, seroepidemiology screening, tropism studies, and bespoke virus and assay development, all designed to deliver reliable, high-throughput results. By leveraging Virion X's validated platforms and protocols, clients can significantly lower screening costs, accelerate research milestones, and maintain data integrity across their studies.
Target Audience
Primary customers are research organisations across industry, academia, and government, including vaccine developers, antiviral drug discovery teams, and public health laboratories conducting epidemiological surveillance.
Features
- Established panel of pseudotyped viruses covering high-consequence epidemic and pandemic viruses, with rapid adaptation to new targets
- High-throughput neutralisation assays to assess vaccine-induced immune responses and antiviral drug efficacy, including resistance screening
- Seroepidemiology screening with multiplexing capabilities to maximise data from limited antibody samples
- Tropism studies using pseudotyped virus platforms to investigate host and tissue permissivity
- Bespoke virus and assay development tailored to specific research requirements not covered by the standard catalogue
- Supporting products including plasmids, detailed production protocols, and control reagents to ensure optimal assay performance